A New Job for Xalkori
The US Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat patients with advanced non-small cell lung cancer (NSCLC) who have tumors with an ROS-1 gene alteration.
New Medication Proves Effective Against Lung Cancer
As scientists continue to look for better and more effective cancer treatments, one new study looked at a promising new medication in the fight against lung cancer.
Lung Cancer Rx Reduced Kidney Function
In 2011, the US Food and Drug Administration fast-tracked the approval of Xalkori (crizotinib) to treat a specific type of non-small cell lung cancer (NSCLC). Since its approval, side effects have been discovered.
Lung Cancer Rx Beats Chemotherapy
Lung cancer is a very complex disease. Depending on the genetic make-up of the cancer cells, lung cancer can be many different diseases. And personalized therapy treats the defective genes individuals patients have.
Targeting Lung Cancer Bad Actor
In the cancer world, a protein called Hsp90 is a bad actor. It helps a number of different cancers survive and thrive. An experimental medication may become Hsp90’s worst nightmare.
New Gene Test IDs Patients for Cancer Drug
Targeted therapy can do wonders. The trick is finding which patients have the genetic mutation or some other alteration that drugs can effectively target.
Targeted Cancer Therapy Casts Wider Net
Targeting cancer gene mutations has been changing the way non-small cell lung cancer ( NSCLC ) is treated. As scientists learn more about the genetic makeup of tumors, more personalized therapy has become available.
An Alternative When Cancer Grows
When non-small cell lung cancer ( NSCLC ) grows again after shrinking on targeted therapy, patients may turn to chemotherapy. Adding local therapy to targeted drugs could offer another solution.
A Game Changer For Lung Cancer
About 5 percent of the 226,000 lung cancers diagnosed every year in the U.S. have a scrambled ALK gene. Usually people with this type of lung cancer are treated with chemotherapy. Now, another drug has been shown to be more effective.
Getting the Best Care for Lung Cancer
In the second of our series on lung cancer, we continue our conversation with one of the nation's experts on the subject. D. Ross Camidge , MD, PhD , is a well-known lung cancer specialist and director of the thoracic oncology clinical program at the University of Colorado.